Syndax Pharma (SNDX)
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes...
- Open
- 19.830
- High
- 20.035
- Low
- 19.670
- Prev. Close
- 19.760
- Volume
- 95.80K
- Turnover
- 1.90M
- Avg Price
- 19.812
- Bid/Ask Ratio
- -63.86%
- Amplitude
- 1.85%
- 52wk High
- 25.590
- Volume Ratio
- 0.62
- Turnover Ratio
- 0.12%
Syndax Pharma Analyst Rating
View moreForecast & Rating
Aug 17, 2026Price forecast
$37.9190.69%
Forecast & RatingStrong buy
12analysts
- Strong buy83.33%
- Buy16.67%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Simplywall · Aug 7 at 06:53 AM
Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts
- Simplywall · Aug 5 at 10:36 PM
Syndax Pharmaceuticals (SNDX) Stock Climbs On Revenue Strength As Losses Persist
- PUBT · Aug 5 at 03:12 PM
Syndax grants stock option awards for 59,250 shares to five new employees
- Tip Ranks · Aug 5 at 10:08 AM
Edding Genor’s Jing Zhu Da Sub-Licensing Deal Collapses After Upstream License Termination
- benzinga_article · Aug 5 at 08:00 AM
Syndax Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results. Also, HC Wainwright & Co. lowered its price target on the stock from $40 to $38.
- TradingView · Aug 5 at 04:20 AM
Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39, Implies 104% Upside
